NCI-2023-04362

A Phase I, Open-label, Multicenter Study of ZL-1218 as a Single Agent and as Combination Therapy with Anti-PD-1 Antibody to Evaluate the Safety, Tolerability, and Pharmacokinetics in Subjects with Advanced Solid Tumor Malignancies

In this Phase I study,  researchers are looking at how a new medicine called ZL-1218 works for people with advanced cancer. They're testing it alone and with another treatment, an anti-PD-1 antibody, that helps the immune system fight cancer. The study is happening in multiple loactions, and the main goal is to find out if ZL-1218 is safe and how effective it is in treating advanced cancer.

Phase I study: First step in testing a new medicine in people, and tests if treatment is safe, determines the right dose, and checks for any side effects.

anti-PD-1: Blocks a specific protein (PD-1) that cancer cells use to hide from the immune system. By blocking this protein, the medicine makes it easier for the immune system to find and attack the cancer cells.

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT05859464

Clinical Trial Site: Sinai

To see all available clinical trials click here.